Plasminogen Activator Inhibitor: a Risk Factor for Myocardial Infarction in Diabetic Patients

Overview

Journal Br Heart J

Specialty Cardiology & Vascular Diseases

Date 1993 Mar 1

PMID 8461220

Citations 7

Authors

R P Gray

J S Yudkin

D L PATTERSON

Affiliations

Soon will be listed here.

Abstract

Objective: To determine whether diabetic patients admitted with acute myocardial infarction have impaired fibrinolytic activity due to raised plasminogen activator inhibitor compared with non-diabetic patients.

Setting: A district general hospital.

Patients: 90 non-diabetic and 38 diabetic patients admitted with acute myocardial infarction.

Results: Both plasminogen activator inhibitor activity and antigen were significantly higher in diabetic than in non-diabetic patients (24.7 (6.8) v 18.5 (6.8) AU/ml; p = 0.0001 and 64.2 (range 13.1 to 328.8) v 38.5 (range 10.9 to 173.7 ng/ml; z = 3.3; p = 0.0008) with a positive correlation between activity and antigen (rs = 0.51; p = 0.0001). In both groups, activity and antigen concentrations were significantly higher than in diabetic and non-diabetic subjects without coronary artery disease (p = 0.002 to 0.0001 for each comparison). Plasminogen activator inhibitor activity correlated significantly with admission plasma glucose (r = 0.32; p = 0.0001), glycated haemoglobin (r = 0.32; p = 0.0001), admission plasma insulin (rs = 0.48; p = 0.001), and Killip grade of heart failure both on admission (rs = 0.27; p = 0.001) and on discharge (rs = 0.22; p = 0.006), but not with cumulative creatine kinase MB isoenzyme release (rs = -0.08). There were similar but weaker correlations between tissue plasminogen activator antigen and admission plasma glucose, glycated haemoglobin, and insulin. In 18 patients (12 non-diabetic and six diabetic) plasminogen activator inhibitor activity was measured between six and 12 months (8.3 (1.6)) after the acute infarct and remained similar to activity on admission (24.8 (1.9) AU/ml (NS) for diabetic and 17.9 (6.9) AU/ml (NS) for non-diabetic patients) and was still significantly higher in diabetic than in non-diabetic patients (p = 0.007).

Conclusion: These results show that diabetic patients have higher plasminogen activator inhibitor activity than non-diabetic patients both on admission with acute myocardial infarction and at follow up six to 12 months later. Raised plasminogen activator inhibitor activity may predispose diabetic patients to myocardial infarction and may also impair pharmacological and spontaneous reperfusion after acute myocardial infarction thus contributing to the poor outcome in these subjects.

Citing Articles

Synopsis of Biomarkers of Atheromatous Plaque Formation, Rupture and Thrombosis in the Diagnosis of Acute Coronary Syndromes.

Udaya R, Sivakanesan R Curr Cardiol Rev. 2022; 18(5):53-62.

PMID: 35410616 PMC: 9896418. DOI: 10.2174/1573403X18666220411113450.

Genotype Variations and Association between PAI-1 Promoter Region (4G/5G and -844G/A) and Susceptibility to Acute Myocardial Infarction and Chronic Stable Angina.

Kumar S, Verma A, Sagar V, Ranjan R, Sharma R, Tomar P Cardiol Res Pract. 2021; 2021:5551031.

PMID: 34258054 PMC: 8257367. DOI: 10.1155/2021/5551031.

The Role of Hemostatic Factors in Atherosclerosis in Patients with Chronic Renal Disease.

Zahran M, Nasr F, Metwaly A, El-Sheikh N, Khalil N, Harba T Electron Physician. 2015; 7(5):1270-6.

PMID: 26435827 PMC: 4590563. DOI: 10.14661/1270.

Serum level of plasminogen activator inhibitor type-1 in addicted patients with coronary artery disease.

Forood A, Malekpour-Afshar R, Mahdavi A Addict Health. 2015; 6(3-4):119-26.

PMID: 25984279 PMC: 4354217.

Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors and Glycaemic Control in Patients with Type 2 Diabetes Mellitus.

Britton M, Denver A, Mohamed-Ali V, Yudkin J Clin Drug Investig. 2008; 16(4):303-17.

PMID: 18370552 DOI: 10.2165/00044011-199816040-00005.

References

Oswald G, Yudkin J . Hyperglycaemia following acute myocardial infarction: the contribution of undiagnosed diabetes. Diabet Med. 1987; 4(1):68-70. DOI: 10.1111/j.1464-5491.1987.tb00833.x. View

Yudkin J, Oswald G . Hyperglycaemia, diabetes and myocardial infarction. Diabet Med. 1987; 4(1):13-8. DOI: 10.1111/j.1464-5491.1987.tb00821.x. View

White H, Norris R, Brown M, Takayama M, Maslowski A, Bass N . Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987; 317(14):850-5. DOI: 10.1056/NEJM198710013171402. View

Almer L, Ohlin H . Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. Thromb Res. 1987; 47(3):335-9. DOI: 10.1016/0049-3848(87)90147-2. View

Auwerx J, Bouillon R, Collen D, Geboers J . Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 1988; 8(1):68-72. DOI: 10.1161/01.atv.8.1.68. View

Lucore C, Sobel B . Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 1988; 77(3):660-9. DOI: 10.1161/01.cir.77.3.660. View

Loskutoff D, Sawdey M, Mimuro J . Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989; 9:87-115. View

Temple R, Carrington C, Luzio S, Owens D, Schneider A, Sobey W . Insulin deficiency in non-insulin-dependent diabetes. Lancet. 1989; 1(8633):293-5. DOI: 10.1016/s0140-6736(89)91306-8. View

Huber K, Rosc D, Resch I, Schuster E, Glogar D, KAINDL F . Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost. 1988; 60(3):372-6. View

10.

Alessi M, Juhan-Vague I, Kooistra T, Declerck P, Collen D . Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 1988; 60(3):491-4. View

11.

Juhan-Vague I, Alessi M, Joly P, Thirion X, Vague P, Declerck P . Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis. 1989; 9(3):362-7. DOI: 10.1161/01.atv.9.3.362. View

12.

Sobey W, Beer S, Carrington C, Clark P, Frank B, Gray I . Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J. 1989; 260(2):535-41. PMC: 1138701. DOI: 10.1042/bj2600535. View

13.

Juhan-Vague I, Roul C, Alessi M, Ardissone J, Heim M, Vague P . Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost. 1989; 61(3):370-3. View

14.

Barbash G, Hod H, Roth A, MILLER H, Rath S, Zahav Y . Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol. 1989; 64(19):1231-5. DOI: 10.1016/0002-9149(89)90559-6. View

15.

Nagi D, Hendra T, Ryle A, Cooper T, Temple R, Clark P . The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1990; 33(9):532-7. DOI: 10.1007/BF00404140. View

16.

Zalewski A, Shi Y, Nardone D, Bravette B, WEINSTOCK P, Fischman D . Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates. Circulation. 1991; 83(5):1685-91. DOI: 10.1161/01.cir.83.5.1685. View

17.

Sane D, Stump D, Topol E, Sigmon K, Kereiakes D, GEORGE B . Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost. 1991; 65(3):275-9. View

18.

Sobel B, Bresnahan G, Shell W, YODER R . Estimation of infarct size in man and its relation to prognosis. Circulation. 1972; 46(4):640-8. DOI: 10.1161/01.cir.46.4.640. View

19.

Davies M, Woolf N, Robertson W . Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. Br Heart J. 1976; 38(7):659-64. PMC: 483064. DOI: 10.1136/hrt.38.7.659. View

20.

DeWood M, Spores J, Notske R, Mouser L, Burroughs R, Golden M . Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980; 303(16):897-902. DOI: 10.1056/NEJM198010163031601. View